Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fish oil-based intravenous fat emulsion for pediatric PN-associated cholestasis (IFALD)
jRCT2021230032Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in parenteral nutrition-associated cholestasis (PNAC), intestinal failure-associated liver disease (IFALD), short bowel syndrome (SBS) and 1 more, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary: Triene/Tetraene (T/T) Ratio at Day 56. Started Nov 2023; status: active, not recruiting.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
parenteral nutrition-associated cholestasis (PNAC)intestinal failure-associated liver disease (IFALD)short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on jRCT2021230032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230032.